Navitoclax (ABT-263)

Catalog No.S1001

Navitoclax (ABT-263) Chemical Structure

Molecular Weight(MW): 974.61

Navitoclax (ABT-263) is a potent inhibitor of Bcl-xL, Bcl-2 and Bcl-w with Ki of ≤ 0.5 nM, ≤1 nM and ≤1 nM in cell-free assays, but binds more weakly to Mcl-1 and A1. Phase 2.

Size Price Stock Quantity  
In DMSO USD 400 In stock
USD 120 In stock
USD 200 In stock
USD 370 In stock
USD 970 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 37 Publications

13 Customer Reviews

  • KP cells (A) and A549 cells (B) were treated with increasing doses of ATN-224 alone or with the BCL2 inhibitor ABT-263, and cell death (96 hours) was determined.

    J Clin Invest, 2014, 124(1): 117-28 . Navitoclax (ABT-263) purchased from Selleck.

    Cell lines are also resistant to dual inhibition of Bcl-xL and Bcl-2 by the inhibitor ABT-263 when dosed with NSC siRNA, but co-dosing ABT-263 with Mcl-1 siRNA decreases compound IC50 similar to that observed with WEHI-539. Representative curves for MDA-MB-157 are shown in f.

    Cell Death Differ, 2015, 10.1038/cdd.2015.73. Navitoclax (ABT-263) purchased from Selleck.

  • ABT-263 has a higher albumin binding affinity than ABT-737. The binding capacity of ABT-737 (solid lines) and ABT-263 (dotted lines) to HSA was investigated using a fluorescence polarization assay. A, to measure binding to site 2 on HSA-IIIA, dansyl sarcosine was used as a probe. In this assay the IC50 was 711 and 37μmol/L for ABT-737 and ABT-263, respectively. B, to measure binding to site 1 on HSA-IIA, dansyl L-glutamate was used as a probe. The IC50 was >1,000 and 145 μmol/L for ABT-737 and ABT-263, respectively.

    Clin Cancer Res 2010 16, 4217-4225. Navitoclax (ABT-263) purchased from Selleck.

    Clin Cancer Res 2010 16, 4217-4225. Navitoclax (ABT-263) purchased from Selleck.

  • Clin Cancer Res 2010 16, 4217-4225. Navitoclax (ABT-263) purchased from Selleck.

    Clin Cancer Res 2010 16, 4217-4225. Navitoclax (ABT-263) purchased from Selleck.

  • Clin Cancer Res 2010 16, 4217-4225. Navitoclax (ABT-263) purchased from Selleck.

    PLoS One 2011 6, e21980. Navitoclax (ABT-263) purchased from Selleck.

  • PLoS One 2011 6, e21980. Navitoclax (ABT-263) purchased from Selleck.

    PLoS One 2011 6, e21980. Navitoclax (ABT-263) purchased from Selleck.

  • Apoptosis induced by BCL2-inhibitors in P-glycoprotein expressing cells. MDCKII wild type or MDR1 cells were exposed to different concentrations of ABT-737 (C) or ABT-263 (D) for 24 h before apoptosis was assessed by flow cytometry using externalization of phosphatidylserine.

    Biochem Biophys Res Commun 2011 408(2), 344-9. Navitoclax (ABT-263) purchased from Selleck.

     

    (A) In vitro generated  Mcl-1-deleted  Arf-/- p185+ cells stably expressing the indicated constructs were treated with indicated doses of navitoclax (ABT-263) for 24 hours after which percent viable cells were determined (propidium iodide negative cells were scored as viable). Each point represents the average of three independent experiments and the error bars denote the SEM.  p185+ Arf-/- cells serve as a control.  (B) Arf -null p185+ cells were treated with navitoclax for 24 hours at indicated doses. Lysates were immunoprecipitated with anti-BIM antibody and immune complexes were resolved and western blotted for MCL-1, BCL-2 (human specific antibody), BCL-XL, BIM, PARP and Actin (loading control). Endogenous BIM serves as the control for equal immunoprecipitation. (E&F) p185+ Arf-/- cells were treated with indicated doses of navitoclax and/or  (E) IM or  (F) DAS for 24 hours after which percent viable cells was determined. Annexin-V and PI negative cells were scored as viable. IL-7 was added to a final concentration of 20 ng/mL.

    Navitoclax (ABT-263) purchased from Selleck.

  •  

    Human Ph+ cell lines:  (A)  OP-1 Ph+ B-ALL  (B) TOM1 Ph+ B-ALL and (C)  BV173 Ph+CML blast crisis cell lines were treated with navitoclax, imatinib (IM) or dasatinib (DAS) at indicated doses for 24 hours after which cell lysates were analyzed for expression of MCL-1, BCL-2, BCL-w, BFL-1 and BCL-XL.  For potentiation experiments, the percentage of viable cells was determined by Annexin-V and PI negativity.

    Navitoclax (ABT-263) purchased from Selleck.

Purity & Quality Control

Choose Selective Bcl-2 Inhibitors

Biological Activity

Description Navitoclax (ABT-263) is a potent inhibitor of Bcl-xL, Bcl-2 and Bcl-w with Ki of ≤ 0.5 nM, ≤1 nM and ≤1 nM in cell-free assays, but binds more weakly to Mcl-1 and A1. Phase 2.
Targets
Bcl-xL [1]
(Cell-free assay)
Bcl-2 [1]
(Cell-free assay)
Bcl-w [1]
(Cell-free assay)
<=0.5 nM(Ki) <=1 nM(Ki) <=1 nM(Ki)
In vitro

ABT-263 is structurally related to ABT-737; it is a disruptor of Bcl-2/Bcl-xL interactions with pro-apoptotic proteins. Overexpression of the prosurvival Bcl-2 family members is commonly associated with tumor maintenance, progression, and chemoresistance. [1] ABT-263 displays the protection afforded by overexpression of Bcl-2 or Bcl-xL with EC50 values of 60 nM and 20 nM, respectively. [1] A wide range of cellular activity is observed with ABT-263 having a 50% growth inhibition (EC50) of 110 nM against the most sensitive line (H146), whereas its activity in the least sensitive line (H82) results in an EC50 at 22 μM. All four cell lines with EC50 values of <400 nM (H146, H889, H1963, and H1417) are also highly sensitive to ABT-737, and the two most resistant lines (H1048 and H82) are similarly resistant to ABT-263. [2]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
EoL-1-cell NEWzfGZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHe0SoNKSzVyPUCuNFA3PjlizszN NF\6[I1USU6JRWK=
MV-4-11 Mn;MS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoPHTWM2OD1yLkCxOVg3KM7:TR?= MUPTRW5ITVJ?
NKM-1 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFvjc3NKSzVyPUCuNFE3QTlizszN NVzUOFRXW0GQR1XS
ML-2 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWCwOW95UUN3ME2wMlAyQTh|IN88US=> NXfpcYU5W0GQR1XS
BV-173 NGrKdXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEGyXY5KSzVyPUCuNFI{OTRizszN NV:0foloW0GQR1XS
RS4-11 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFvKOnBKSzVyPUCuNFI2QDdizszN M4XwR3NCVkeHUh?=
HL-60 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYLJR|UxRTBwMEK5NFgh|ryP M4nPV3NCVkeHUh?=
KY821 MoTVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmjoTWM2OD1yLkCyPVc2KM7:TR?= NUm4NWJnW0GQR1XS
ECC10 NWH6T4JTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYHJR|UxRTBwMEO3PVIh|ryP NEHFclVUSU6JRWK=
NCI-H720 M17tcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mk\vTWM2OD1yLkC0NFEyKM7:TR?= M2\BR3NCVkeHUh?=
QIMR-WIL NV75OYxbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlWwTWM2OD1yLkC0Nlg4KM7:TR?= NE\yN2xUSU6JRWK=
KG-1 M1WxTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGPlV4lKSzVyPUCuNFQ1QDZizszN MXXTRW5ITVJ?
TGW NGqzcJdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVrYPVJPUUN3ME2wMlA1PjN|IN88US=> NVTRZ4k1W0GQR1XS
ATN-1 MoDiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEXsUY9KSzVyPUCuNFQ4OzNizszN NFX6OpdUSU6JRWK=
RH-18 NVm5dIhkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NY[wPXV3UUN3ME2wMlA3ODR6IN88US=> NICwdVBUSU6JRWK=
EW-18 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV7JR|UxRTBwME[4OFEh|ryP NXHFOHZtW0GQR1XS
NB17 NIrwU4ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH7tV2xKSzVyPUCuNFcyOjRizszN MVrTRW5ITVJ?
SK-NEP-1 MorGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXTJR|UxRTBwMEeyNVMh|ryP Ml;PV2FPT0WU
P12-ICHIKAWA NUjp[IxFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUTJR|UxRTBwMEe3O|gh|ryP MUTTRW5ITVJ?
KARPAS-45 M4DiO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NU[wbYJlUUN3ME2wMlA4QDF3IN88US=> MmrRV2FPT0WU
EW-3 Mke0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXP5Omc5UUN3ME2wMlA5ODV|IN88US=> NXrBOnNvW0GQR1XS
NB13 NY\SNmlwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MU\JR|UxRTBwMEiyNFMh|ryP MVTTRW5ITVJ?
NCI-H209 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn;RTWM2OD1yLkC4O|A1KM7:TR?= M{H1THNCVkeHUh?=
NCI-H1092 MlLjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUPJR|UxRTBwMUCyO|Uh|ryP Mlz1V2FPT0WU
NH-12 NHK4dnRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoizTWM2OD1yLkGwO|Q1KM7:TR?= MkX5V2FPT0WU
697 NFrVXZNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1\4Z2lEPTB;MD6xNFg{QSEQvF2= Mkf4V2FPT0WU
KE-37 NEPh[3BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NG[1b3RKSzVyPUCuNVE{PyEQvF2= M3[ydHNCVkeHUh?=
MOLT-4 NGTTR5hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{L6R2lEPTB;MD6xOVE3QSEQvF2= M{n4[3NCVkeHUh?=
CHP-134 M2DrPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH;lO3hKSzVyPUCuNVY{ODZizszN MV;TRW5ITVJ?
D-283MED MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWrBbVFNUUN3ME2wMlE4Pjh4IN88US=> NYfTcndRW0GQR1XS
LU-135 NHzOUphIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmS2TWM2OD1yLkG4OVUzKM7:TR?= M134WnNCVkeHUh?=
LU-134-A MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH;BNGRKSzVyPUCuNVg3PzFizszN NUTKVGl5W0GQR1XS
EM-2 NUnSS2FDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX6zfXhSUUN3ME2wMlE6QTF6IN88US=> M2LsR3NCVkeHUh?=
LU-139 NG\5XnJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2[5S2lEPTB;MD6yNFQ6QCEQvF2= M1X4SXNCVkeHUh?=
ALL-PO MkK0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXX6TWk5UUN3ME2wMlIyQTh6IN88US=> M4m3bnNCVkeHUh?=
NB12 M3;MRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MW\JR|UxRTBwMkOxNVUh|ryP MnKxV2FPT0WU
KP-N-YN MkHCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYr3RmZOUUN3ME2wMlI{PTd|IN88US=> M3\U[3NCVkeHUh?=
BEN M1T6Zmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2rPZWlEPTB;MD6yN|k3QCEQvF2= NUfmPFJPW0GQR1XS
HCC1569 NYXBUJdiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1:ze2lEPTB;MD6yOVExPiEQvF2= MYXTRW5ITVJ?
HuO9 NHXXdXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NE\tcnRKSzVyPUCuNlY4OTVizszN NH7kcpNUSU6JRWK=
WM-115 M3Gx[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUnJR|UxRTBwMke3N|gh|ryP NEf4WpVUSU6JRWK=
CCRF-CEM Mly3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFPncHRKSzVyPUCuN|M2OjlizszN M2C0cHNCVkeHUh?=
IST-SL1 M{j5NGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1XiXWlEPTB;MD6zOVM1OyEQvF2= MlO4V2FPT0WU
BE-13 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1rXdmlEPTB;MD6zOlQ2QSEQvF2= MXLTRW5ITVJ?
COR-L88 NGLoSFhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFnxd2hKSzVyPUCuN|Y2PCEQvF2= M3XnXnNCVkeHUh?=
DOHH-2 NVXl[VBsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NW\p[VZTUUN3ME2wMlQyODJ|IN88US=> M3TFUXNCVkeHUh?=
A704 NXXzR4VHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWLJR|UxRTBwNEK2O{DPxE1? M3LaRnNCVkeHUh?=
KNS-81-FD MnvRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{HETmlEPTB;MD60OFAyPyEQvF2= NGfoOnBUSU6JRWK=
RPMI-8226 NXf5[FNtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3HG[GlEPTB;MD60OVY2OiEQvF2= MYDTRW5ITVJ?
TGBC24TKB M3jSb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH\HfXBKSzVyPUCuOFU4PzhizszN NWm5W2hUW0GQR1XS
NCI-H1304 NF:wfWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFTGXI9KSzVyPUCuOFYyPTdizszN M4H6THNCVkeHUh?=
MOLT-13 MoPKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYHJR|UxRTBwNE[2NVMh|ryP MmfIV2FPT0WU
EW-22 NEH6PJBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGHUR|JKSzVyPUCuOFY3PzFizszN NYG4XnF3W0GQR1XS
MS-1 NH\nelNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmLDTWM2OD1yLkS2PVM{KM7:TR?= NE\CdmhUSU6JRWK=
RMG-I NIrVfXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MknoTWM2OD1yLkS5OFY1KM7:TR?= M{DsdnNCVkeHUh?=
NTERA-S-cl-D1 NXzsfGpxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUezfnVDUUN3ME2wMlUxODF7IN88US=> Mlq2V2FPT0WU
NCI-H1048 NWrOUlNXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M324NmlEPTB;MD61NFk2OyEQvF2= MoS2V2FPT0WU
SW1417 NXSwbY5YT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIr2PIVKSzVyPUCuOVU1OzhizszN NFv6dVJUSU6JRWK=
DB M1v1fmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGm0XG9KSzVyPUCuOVcxQCEQvF2= NHrSRWhUSU6JRWK=
MEG-01 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFXaNIFKSzVyPUCuOVg{OiEQvF2= NX7YbYgyW0GQR1XS
EW-13 M3XLbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVXJR|UxRTBwNUizOFEh|ryP MWrTRW5ITVJ?
LAMA-84 M1:5NWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFy1So1KSzVyPUCuOVkzODdizszN MYLTRW5ITVJ?
J-RT3-T3-5 M3jUSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoPBTWM2OD1yLk[wPFA5KM7:TR?= MnL2V2FPT0WU
MOLT-16 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkjHTWM2OD1yLk[1NlY1KM7:TR?= M3jZZnNCVkeHUh?=
DU-4475 NFjhXJRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHPs[3JKSzVyPUCuOlU1OjdizszN MojvV2FPT0WU
HAL-01 MomyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFTSeolKSzVyPUCuO|I2PDlizszN M1XiTHNCVkeHUh?=
RD NXvkeHdiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX\sOJBXUUN3ME2wMlc2QDl7IN88US=> M4jZWHNCVkeHUh?=
OAW-28 NYnGT2JNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXHJR|UxRTBwN{izO{DPxE1? MWnTRW5ITVJ?
HCC38 NFTiTY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIDYd|dKSzVyPUCuPFAyQSEQvF2= M2jVOHNCVkeHUh?=
NMC-G1 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYL1SXhuUUN3ME2wMlgyOTJzIN88US=> M2DVUnNCVkeHUh?=
EW-16 NU\qS5JnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NI[xc3BKSzVyPUCuPFE{OjhizszN M1PVNnNCVkeHUh?=
DU-145 M4H3TWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4L4SGlEPTB;MD64PVkzOyEQvF2= NIjyVWlUSU6JRWK=
HPAF-II NWLWbZVHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MofITWM2OD1yLkmyOlI5KM7:TR?= MoPGV2FPT0WU
A427 MljqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUf3eoV4UUN3ME2wMlk{ODJ{IN88US=> MlnjV2FPT0WU
PA-1 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoLXTWM2OD1yLkm1OlQzKM7:TR?= NGj0T4ZUSU6JRWK=
OAW-42 MkX0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1fkRmlEPTB;MD65OlE1PiEQvF2= MUTTRW5ITVJ?
L-428 M4PUUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUDld5lPUUN3ME2xMlAyOjVizszN M1i3N3NCVkeHUh?=
COLO-824 M3\Yd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NG\KOGdKSzVyPUGuNFE4ODhizszN NWXwZYNjW0GQR1XS
P30-OHK MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV6y[XV3UUN3ME2xMlA1Pjh6IN88US=> M1;sZ3NCVkeHUh?=
NCI-H2170 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGfZ[m5KSzVyPUGuNFYzOyEQvF2= MljIV2FPT0WU
HCC2998 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NU\qdoVvUUN3ME2xMlA4OTN3IN88US=> NFPt[VBUSU6JRWK=
NB14 NV23Xo15T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn;jTWM2OD1zLkGzO|Q5KM7:TR?= NIjmRXZUSU6JRWK=
TGBC1TKB NV7heYNST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYnJR|UxRTFwMUSxOVIh|ryP MlPjV2FPT0WU
KP-N-YS NI\SO2dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{fj[2lEPTB;MT6xOlI{PiEQvF2= NUe3d4NTW0GQR1XS
CAL-120 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVrJR|UxRTFwMU[0Nlkh|ryP MYrTRW5ITVJ?
SBC-1 NInyc|dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NInPd4RKSzVyPUGuNVkxPTNizszN Mnf6V2FPT0WU
C32 NHvtO2VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUTJR|UxRTFwMUmwPFgh|ryP NIDXVI5USU6JRWK=
HCC2157 M4fUOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{DGXWlEPTB;MT6xPVQ6PCEQvF2= M3jTO3NCVkeHUh?=
COLO-792 M3r2XGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWTI[Yt2UUN3ME2xMlIxODdzIN88US=> NIK3Z4NUSU6JRWK=
ES7 MnnHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYXRcmV3UUN3ME2xMlI4QTVzIN88US=> MWrTRW5ITVJ?
HEL M{\2Zmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M13pdGlEPTB;MT6zNVAzQSEQvF2= MkfvV2FPT0WU
ES4 NVnMfnRvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn;MTWM2OD1zLkO0PVk5KM7:TR?= M2TIOnNCVkeHUh?=
NCI-SNU-1 NXznVHdCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{O5T2lEPTB;MT6zOlU2PSEQvF2= MlHPV2FPT0WU
MDA-MB-415 NWrWO|E6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1;kZ2lEPTB;MT6zPFg2KM7:TR?= MlzzV2FPT0WU
NCI-H2342 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUHJR|UxRTFwNECyOlkh|ryP NVH6dW5CW0GQR1XS
NB69 M2HafWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXrDR5NEUUN3ME2xMlQ3OjdzIN88US=> MXrTRW5ITVJ?
D-247MG M4f0Tmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn3tTWM2OD1zLkWxNVIzKM7:TR?= MnjCV2FPT0WU
SCC-4 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2GyUGlEPTB;MT61PVg5PyEQvF2= NY[wNXUxW0GQR1XS
HuH-7 NEGwclZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmLrTWM2OD1zLk[3Nlk{KM7:TR?= MmSxV2FPT0WU
A388 NYfGfFVMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH\MV|dKSzVyPUGuOlg4OjRizszN M{jTU3NCVkeHUh?=
Calu-3 NIXJ[mFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmrPTWM2OD1zLkewOlk4KM7:TR?= NV35dWlxW0GQR1XS
NCI-H1648 NWjCUnZWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXHnbHNCUUN3ME2xMlcyPDF6IN88US=> NVHoWXBsW0GQR1XS
NCI-H2052 NEO2eG9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmH1TWM2OD1zLkeyNlAyKM7:TR?= NHzxfVhUSU6JRWK=
Ramos-2G6-4C10 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV7vfVRpUUN3ME2xMlc{PjV4IN88US=> MX7TRW5ITVJ?
DEL MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXfTeGJsUUN3ME2xMlc1Pjl{IN88US=> Ml[0V2FPT0WU
SNU-423 MoLyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4Xxe2lEPTB;MT63PFE2PyEQvF2= MljwV2FPT0WU
COR-L23 NHj3e25Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF;J[YZKSzVyPUGuO|k5PzRizszN NXL5TnA{W0GQR1XS
OMC-1 M1LidWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoftTWM2OD1zLki2NFE3KM7:TR?= MmTxV2FPT0WU
EW-11 M4C1V2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX;XU3dKUUN3ME2xMlk2PjV5IN88US=> MVTTRW5ITVJ?
HSC-3 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHi5R2xKSzVyPUGuPVY{PjVizszN NWX4cGRDW0GQR1XS
MLMA MnjlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYLJR|UxRTFwOU[2O|ch|ryP NW\XTlh3W0GQR1XS
RCM-1 M3:4RWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUD2d29UUUN3ME2yMlAxOzl7IN88US=> NXHtXVQ5W0GQR1XS
MFE-280 M1nVS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFnzcFFKSzVyPUKuNFI5PDhizszN M3LCVXNCVkeHUh?=
ES8 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV7se2JjUUN3ME2yMlI2PDdzIN88US=> M4nMOXNCVkeHUh?=
TE-11 MnXFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MW\JR|UxRTJwMkm0O|Mh|ryP MWPTRW5ITVJ?
HuO-3N1 NXi5OmpYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2W1d2lEPTB;Mj60PFc5KM7:TR?= NXTLV|dnW0GQR1XS
MHH-NB-11 MmC1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NELBUYRKSzVyPUKuOVEyPThizszN NXS2OXg5W0GQR1XS
TGBC11TKB M4jFcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUTQXJprUUN3ME2yMlU4PjhzIN88US=> NV;yfVYyW0GQR1XS
HOP-92 M4Tp[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoTXTWM2OD1{LkW4O|Q{KM7:TR?= MWfTRW5ITVJ?
IGR-1 Mn3GS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIX1WoZKSzVyPUKuOlIxOzVizszN M2rkTHNCVkeHUh?=
GOTO NVTZWIpxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXrSWVVTUUN3ME2yMlY2Ozd5IN88US=> MUTTRW5ITVJ?
NCI-H1650 M1zWdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NW\3NoIzUUN3ME2yMlczOjF3IN88US=> MoDoV2FPT0WU
NCI-H1581 NUj2dYtbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVPWOm54UUN3ME2yMlc6PjhzIN88US=> NX3MO|NWW0GQR1XS
NCI-H2405 M{HtSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnPMTWM2OD1{LkiyO|gzKM7:TR?= M4LidXNCVkeHUh?=
U-118-MG M3PNcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYTJR|UxRTJwOU[0PVEh|ryP NUTNNlk6W0GQR1XS
DoTc2-4510 M1;uOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV3uV3FMUUN3ME2zMlAyPDF5IN88US=> MUDTRW5ITVJ?
NCI-H596 NXjxNVR[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHzHeWRKSzVyPUOuNFQ6QTdizszN NXfQW3Q2W0GQR1XS
MPP-89 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4jrXWlEPTB;Mz6wOVY3PiEQvF2= M1jU[nNCVkeHUh?=
GCIY MnyxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUXxflRwUUN3ME2zMlIxPDlzIN88US=> M1HpbHNCVkeHUh?=
SW626 NUn4NoNzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV;JR|UxRTNwMkS1OFMh|ryP MmPoV2FPT0WU
OCI-AML2 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHL1Z3RKSzVyPUOuN|EzPzJizszN M13RO3NCVkeHUh?=
NBsusSR NUfKUI85T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGPwcFJKSzVyPUOuN|Q6OzhizszN MWHTRW5ITVJ?
AN3-CA NWXDPY5KT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnS1TWM2OD1|LkS0NlM5KM7:TR?= MY\TRW5ITVJ?
EFM-19 NHjQOWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXnJR|UxRTNwNEizN|kh|ryP MWnTRW5ITVJ?
RVH-421 MmPrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmrkTWM2OD1|LkW2PFc4KM7:TR?= MXTTRW5ITVJ?
5637 MnHKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3v1cWlEPTB;Mz62NVExOyEQvF2= M3HFUXNCVkeHUh?=
PANC-08-13 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIDkb3RKSzVyPUOuOlM1PzJizszN NIH3UYFUSU6JRWK=
H9 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWnFUXFLUUN3ME2zMlY4OTR2IN88US=> MmjvV2FPT0WU
KARPAS-299 MkO2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUTyOmVkUUN3ME2zMlY4OzZzIN88US=> NYnneG9QW0GQR1XS
TE-5 NYr2S3QzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlPRTWM2OD1|LkewO|A6KM7:TR?= NUXPVYxNW0GQR1XS
NOS-1 M1jnc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkPGTWM2OD1|Lke5PFM1KM7:TR?= NVrCTXFSW0GQR1XS
HH NV6wUldKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1HlXWlEPTB;Mz64N|g3QCEQvF2= MnXwV2FPT0WU
769-P NWPO[ZNbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV;JR|UxRTNwOEm1NUDPxE1? NEXabYxUSU6JRWK=
CHP-212 M2rmZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXi3RZVQUUN3ME2zMlkzPTR7IN88US=> NF:0WmpUSU6JRWK=
NCI-H82 MlvUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVrQSm9pUUN3ME2zMlk2QTN4IN88US=> NHP3PG5USU6JRWK=
Mo-T M1qzUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkixTWM2OD12LkC0N|EzKM7:TR?= MlHnV2FPT0WU
BB65-RCC MmLHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIHOcmlKSzVyPUSuNFQ{QTlizszN M3HKfXNCVkeHUh?=
SW1990 M1i4RWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFrWfpRKSzVyPUSuNFU6ODhizszN NXn5PYVSW0GQR1XS
LK-2 Mk\qS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MljmTWM2OD12LkGxNlk{KM7:TR?= M2DPT3NCVkeHUh?=
ES5 MlT2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MknLTWM2OD12LkGzPVg2KM7:TR?= NUXpcXVmW0GQR1XS
JVM-3 NVe4cXNtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3XSdGlEPTB;ND6xPFIzOiEQvF2= NXH5fVN3W0GQR1XS
RPMI-7951 NGXhSXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mk\GTWM2OD12LkKyOFE{KM7:TR?= NVPkcGh3W0GQR1XS
Calu-6 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWfJR|UxRTRwMke4PFEh|ryP NUPXOHh[W0GQR1XS
LC-2-ad MkHXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUTJR|UxRTRwMkm1Olgh|ryP M{\CdXNCVkeHUh?=
SW954 NU\LWIJFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4jaZmlEPTB;ND6yPVY3KM7:TR?= NV3XN4k3W0GQR1XS
H-EMC-SS MlfNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYTJR|UxRTRwM{G4N|Eh|ryP M3jENHNCVkeHUh?=
ES3 NGDweXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mkm3TWM2OD12LkO1OFQyKM7:TR?= M1jpZXNCVkeHUh?=
no-11 M1rJSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF;WS5lKSzVyPUSuN|U2PTRizszN NES4UFFUSU6JRWK=
LAN-6 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn\DTWM2OD12LkS1NVg6KM7:TR?= M1vlSHNCVkeHUh?=
FTC-133 MkH6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnGwTWM2OD12LkWzPVUh|ryP MUPTRW5ITVJ?
8505C NHq1RmdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnvITWM2OD12LkW0NlMh|ryP Mlv0V2FPT0WU
SW620 MnHhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlLXTWM2OD12LkW3NFU4KM7:TR?= M2XVUXNCVkeHUh?=
BCPAP NHLLfmdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MY\JR|UxRTRwNkO0PFEh|ryP MWDTRW5ITVJ?
SK-LU-1 M3v0bWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2rWO2lEPTB;ND62OlA5QSEQvF2= NUnUTpRkW0GQR1XS
NCI-H1623 M3PLWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUjJR|UxRTRwN{CyNlgh|ryP M1nVSHNCVkeHUh?=
C2BBe1 M4LjPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFLwZ4JKSzVyPUSuO|QxODhizszN NVO4NHp3W0GQR1XS
GP5d MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFr0PY1KSzVyPUSuO|g{QDhizszN NHjmUFJUSU6JRWK=
NB6 NYXWb29GT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXPEc4VRUUN3ME20Mlg3OjB2IN88US=> NIDZU29USU6JRWK=
MDA-MB-157 NGXSWJRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{jnXWlEPTB;ND64PFc3KM7:TR?= NGP1bWdUSU6JRWK=
UMC-11 M3z3d2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MU\JR|UxRTRwOEi5OlQh|ryP MkPmV2FPT0WU
HCC1419 M1nEcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlLZTWM2OD12LkmwNFY{KM7:TR?= NVW4bVRTW0GQR1XS
NCI-H2029 Mof6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NICzblhKSzVyPUSuPVQyQDVizszN M1nsXXNCVkeHUh?=
LXF-289 M{PjUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUXRSZJwUUN3ME21MlA{PzF7IN88US=> NXrreYt5W0GQR1XS
KINGS-1 Ml\RS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn\kTWM2OD13LkC3O|Q1KM7:TR?= NF3lOHlUSU6JRWK=
HD-MY-Z MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlLPTWM2OD13LkKzPVY6KM7:TR?= M3LhUHNCVkeHUh?=
ESS-1 NHHmOWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1nrOGlEPTB;NT6yOVU6PyEQvF2= NV\LZolFW0GQR1XS
GI-1 NF;nWG9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MorWTWM2OD13LkK3PVI3KM7:TR?= Ml3pV2FPT0WU
RPMI-2650 MonMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF\IVolKSzVyPUWuN|YyPiEQvF2= NH;HXmxUSU6JRWK=
IA-LM NGHhdo5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUL1TnVpUUN3ME21MlM6QDdzIN88US=> MkLnV2FPT0WU
KP-4 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2j1cWlEPTB;NT60OlM{PCEQvF2= MWLTRW5ITVJ?
G-402 M2rnW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1uxZ2lEPTB;NT61NVg3PSEQvF2= M{PRbHNCVkeHUh?=
OS-RC-2 M2jYcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NITxRmhKSzVyPUWuOVI3ODRizszN MYLTRW5ITVJ?
NCI-H1155 M3nUN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXz1SVhNUUN3ME21MlU1QTV3IN88US=> NWf4NZE6W0GQR1XS
OE19 NXvn[IN6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3;SUmlEPTB;NT62PFYzPCEQvF2= M3e0ZXNCVkeHUh?=
U-2-OS NF;WPVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFLKemlKSzVyPUWuPFkxOTNizszN NGfRPGJUSU6JRWK=
SCC-15 NUfNXYhLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3nqVmlEPTB;NT65N|Y3OiEQvF2= M1O4dXNCVkeHUh?=
NCI-H630 Mnq3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnLvTWM2OD13Lkm5OFA1KM7:TR?= MnfDV2FPT0WU
PFSK-1 MkHtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYrScpp{UUN3ME22MlA2OjV7IN88US=> MVXTRW5ITVJ?
NCI-H1770 NHXsbGpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{XNZ2lEPTB;Nj6yNFg4PCEQvF2= M4LFT3NCVkeHUh?=
SK-MEL-3 M{TFdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4rTdWlEPTB;Nj60NlkyPSEQvF2= MoezV2FPT0WU
LB1047-RCC NWTMWYhRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlHKTWM2OD14LkS3OlI2KM7:TR?= M2LzSHNCVkeHUh?=
NCI-H446 NXX6U5B6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIjVdW1KSzVyPU[uOlI6OjVizszN NW\DSZZTW0GQR1XS
SW780 MlnNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWrHRlRQUUN3ME22MlcxOTh3IN88US=> M4T1PXNCVkeHUh?=
NEC8 NFGzWnVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWHnVFNQUUN3ME22Mlc3PjNizszN NESzPI1USU6JRWK=
NOMO-1 NVzBRodTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVr1dHN6UUN3ME22Mlc5OTFzIN88US=> NYKxNmZ1W0GQR1XS
COLO-668 M{m0bGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVrWPHRTUUN3ME22Mlg1Ozh5IN88US=> MWXTRW5ITVJ?
MC116 M4e0TWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIfHTm5KSzVyPU[uPVM5QTdizszN MnjBV2FPT0WU
HCC1937 M4jUWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2CzVWlEPTB;Nj65PVI2OSEQvF2= NHjlbZNUSU6JRWK=
NCI-N87 NWfLOXU5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWTUNVk5UUN3ME23MlE6Ojl|IN88US=> MXfTRW5ITVJ?
COLO-320-HSR NWT6XpFoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX;Ncml1UUN3ME23MlIzPzN6IN88US=> NFXLU5RUSU6JRWK=
HCC1806 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXvJR|UxRTdwMk[wOFQh|ryP NIjkNpVUSU6JRWK=
OVCAR-3 NUjLZ2hOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWD4VHpDUUN3ME23MlM{ODN6IN88US=> MYXTRW5ITVJ?
NUGC-3 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnW5TWM2OD15LkO5Olk1KM7:TR?= MoXwV2FPT0WU
SW1783 NHzuXY9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWC2R457UUN3ME23MlQ{OTd3IN88US=> M2fQc3NCVkeHUh?=
GCT MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVuxdGFmUUN3ME23MlU3QTB4IN88US=> M4jPZ3NCVkeHUh?=
NCI-H2126 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHrYN4VKSzVyPUeuO|M3OjVizszN MYXTRW5ITVJ?
MEL-HO M3zkZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXXONllGUUN3ME23Mlc4ODV2IN88US=> NWD4bIhVW0GQR1XS
CAPAN-1 NX3rXldST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVXJR|UxRTdwN{ezOVch|ryP M2rjRnNCVkeHUh?=
SW756 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHrTWXJKSzVyPUeuO|g{OzNizszN M1\HcXNCVkeHUh?=
SKG-IIIa MnTCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn\0TWM2OD15LkixPFkzKM7:TR?= NHK0PHlUSU6JRWK=
HCE-T MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MU\JR|UxRTdwOEe3PFMh|ryP MkHlV2FPT0WU
Ca-Ski NF33b5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1OzWmlEPTB;Nz65PVM5OyEQvF2= NEiyfIdUSU6JRWK=
COLO-684 NHHPZZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEPRb|BKSzVyPUiuNFE5OThizszN M{DJNHNCVkeHUh?=
KYSE-70 Mn;yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHP1ZodKSzVyPUiuNFc4OjlizszN MmTiV2FPT0WU
TI-73 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGX2R|JKSzVyPUiuNlU5PTFizszN Mn;aV2FPT0WU
BT-20 M1fUUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF\VZXhKSzVyPUiuNlYxPTJizszN NEG3VXJUSU6JRWK=
MHH-ES-1 MkDES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIPGOGZKSzVyPUiuOVE5OzRizszN NYDrVGpnW0GQR1XS
TE-12 NIrndoxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEfPOlJKSzVyPUiuOVk6OzFizszN M3:5R3NCVkeHUh?=
YH-13 NVPDfGRpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYf4TmhFUUN3ME24MlYyODB6IN88US=> MWPTRW5ITVJ?
SF126 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIqwfphKSzVyPUiuPFM5PjVizszN MnnjV2FPT0WU
J82 MnHsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkfjTWM2OD16LkmwNFM5KM7:TR?= M4LFeHNCVkeHUh?=
RCC10RGB M1PMZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUG4ZVdIUUN3ME24Mlk6PTZzIN88US=> M135b3NCVkeHUh?=
SK-UT-1 M1:zfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYXJR|UxRTlwMES5OFUh|ryP M4O4TXNCVkeHUh?=
LB2241-RCC NX30PG5VT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{OxO2lEPTB;OT6xPVE{PyEQvF2= MY\TRW5ITVJ?
LB996-RCC NFvQR49Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYXJR|UxRTlwMUm4PUDPxE1? M2DaS3NCVkeHUh?=
EPLC-272H NYTWRoltT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4DBRWlEPTB;OT6zO|Y2PyEQvF2= MonQV2FPT0WU
CTV-1 M4L2WGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVzJR|UxRTlwNU[1N|Ih|ryP M3rOSHNCVkeHUh?=
HSC-2 MoG0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWTUUnF5UUN3ME25MlU4PTVizszN MX7TRW5ITVJ?
SK-MEL-28 NEnXcm9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGrSeGVKSzVyPUmuOlE5QTNizszN M{TH[HNCVkeHUh?=
MMAC-SF NGL6RnlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUXjT|N3UUN3ME25MlY5PzVizszN M2fYbnNCVkeHUh?=
CP50-MEL-B NVj3T|ZnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mnj5TWM2OD17Lke1O|gzKM7:TR?= Mn7xV2FPT0WU
HT-1080 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnnWTWM2OD17Lke3O|M6KM7:TR?= M2r0WnNCVkeHUh?=
HEC-1 NHfOZmFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV;JR|UxRTFyLkOzOVIh|ryP MXTTRW5ITVJ?
AGS Mlr5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnLvTWM2OD1zMD6zO|Qh|ryP NHLSO2NUSU6JRWK=
GAMG M{nLVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV\VNG9XUUN3ME2xNE42OTZ{IN88US=> NV;kS2RIW0GQR1XS
SW48 NUTSdZZKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MorNTWM2OD1zMD61NVg6KM7:TR?= NXPpSpM4W0GQR1XS
U031 M1viPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MW\JR|UxRTFyLkW5NFgh|ryP MkTQV2FPT0WU
OVCAR-5 NIXxPGlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4HSfGlEPTB;MUCuOlQzQSEQvF2= MULTRW5ITVJ?
SF295 MnizS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkX0TWM2OD1zMD62O|A1KM7:TR?= MY\TRW5ITVJ?
BHT-101 NV\TVGlsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mnr4TWM2OD1zMD63NVc4KM7:TR?= M1HPW3NCVkeHUh?=
VMRC-RCZ M3nGR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{jPU2lEPTB;MUGuN|IxOSEQvF2= MY\TRW5ITVJ?
ACHN M1PCSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUnJR|UxRTFzLkSyNVEh|ryP MWnTRW5ITVJ?
NCI-H526 M1rtOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4SzN2lEPTB;MUGuOVA1OyEQvF2= M3HET3NCVkeHUh?=
MN-60 NFjXZXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3z0NmlEPTB;MUGuOVM6KM7:TR?= NGrIRnVUSU6JRWK=
NCI-H2291 M1PiRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmTxTWM2OD1zMT61OFY3KM7:TR?= MlTOV2FPT0WU
SCC-25 M1u1ZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX3BOGJqUUN3ME2xNU44PTV4IN88US=> MYDTRW5ITVJ?
SK-MEL-2 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGn1Z|BKSzVyPUGxMlc3OzdizszN NXm5T4NtW0GQR1XS
SN12C NVPlS5Y3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX;VZ2U4UUN3ME2xNU46OzV3IN88US=> M1;wfXNCVkeHUh?=
NCI-H69 NWPSOlJ2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV7rSmlIUUN3ME2xNk41OjN2IN88US=> NUnL[5RjW0GQR1XS
ME-180 Mo\OS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2DxdmlEPTB;MUKuO|A2PCEQvF2= M3XxcnNCVkeHUh?=
MC-IXC MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYXJR|UxRTF{Lke1NVgh|ryP NWXRfWNVW0GQR1XS
NCI-H2347 Mon4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV7MU2pFUUN3ME2xNk44PjF2IN88US=> MX7TRW5ITVJ?
M059J MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml3KTWM2OD1zMj63O|I4KM7:TR?= M1fwNXNCVkeHUh?=
A2058 NG\5PJNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX3mZmRNUUN3ME2xNk45PjhzIN88US=> NHT6XVRUSU6JRWK=
VA-ES-BJ MoHjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MojkTWM2OD1zMj64O|g2KM7:TR?= MV\TRW5ITVJ?
Ca9-22 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVTJR|UxRTF{Lkm0OVEh|ryP MoPyV2FPT0WU
KNS-42 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{\3bWlEPTB;MUKuPVk5PCEQvF2= MWTTRW5ITVJ?
LoVo NFGzU4xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVLJR|UxRTF|LkKzNVMh|ryP MVzTRW5ITVJ?
AM-38 NI\iTnJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV\JR|UxRTF|LkK1OlYh|ryP NWXsWGZLW0GQR1XS
NB5 MkLlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mmi4TWM2OD1zMz6zO|UzKM7:TR?= MlS4V2FPT0WU
L-363 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3v0[GlEPTB;MUOuOFA{OyEQvF2= NYnUeZhXW0GQR1XS
SK-MEL-30 NHHsSFBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NInpR3lKSzVyPUG0MlA3PDVizszN MX7TRW5ITVJ?
NCI-H1563 MkXQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoTDTWM2OD1zND62NFM6KM7:TR?= NHf1WWZUSU6JRWK=
NCI-H2228 M3\MV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUHJR|UxRTF2Lk[wO|ch|ryP NHvaUotUSU6JRWK=
MFM-223 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3fQcWlEPTB;MUWuNVgyOyEQvF2= NI[ySIdUSU6JRWK=
LB831-BLC MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVXJR|UxRTF3LkK3Olch|ryP MnjuV2FPT0WU
SW872 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUi0[mMyUUN3ME2xOU4{ODh4IN88US=> NYLDVmZWW0GQR1XS
NCI-H522 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3;uXGlEPTB;MUWuN|MxPiEQvF2= MUXTRW5ITVJ?
EW-1 NV\sWndZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX;xWoh{UUN3ME2xOU42PDZ{IN88US=> NH;n[4dUSU6JRWK=
HN MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVuwV5RQUUN3ME2xOU42QTR{IN88US=> NUfTWW9mW0GQR1XS
SW837 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NULpZ4R7UUN3ME2xOU44QDR5IN88US=> NFP4WGtUSU6JRWK=
SCC-9 M4n6R2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUjJR|UxRTF3LkixNVQh|ryP MWLTRW5ITVJ?
MKN7 Mn;lS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml3qTWM2OD1zNT65O|MzKM7:TR?= M{DyW3NCVkeHUh?=
KYSE-410 M4rDXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX71WldCUUN3ME2xOk42QTFizszN NIDhRo5USU6JRWK=
SK-N-DZ MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWPOSYZrUUN3ME2xOk43OTF4IN88US=> MWjTRW5ITVJ?
COR-L105 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXq2dYlwUUN3ME2xOk43PTJ6IN88US=> M4LidHNCVkeHUh?=
LB2518-MEL M1TQSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUDzOnVvUUN3ME2xOk45Ozh7IN88US=> MofnV2FPT0WU
OVCAR-4 MlvDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3LGfmlEPTB;MU[uPFg3OiEQvF2= NVG5eIdtW0GQR1XS
TK10 M3TWZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkDCTWM2OD1zNj65OFc{KM7:TR?= MWjTRW5ITVJ?
KNS-62 NEW3eYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYTMOoljUUN3ME2xOk46Pzd5IN88US=> Mn3mV2FPT0WU
RPMI-8866 M1G0TWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVzJR|UxRTF5LkG3N|Ih|ryP NX3rc5dKW0GQR1XS
HuP-T4 MljiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2TqdGlEPTB;MUeuNlQ6PSEQvF2= M{HDU3NCVkeHUh?=
CGTH-W-1 NUDsOItWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXXGO5JVUUN3ME2xO{42OjF7IN88US=> NUPT[5BuW0GQR1XS
T-24 M{Xa[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXzJR|UxRTF5LkWzOFch|ryP NHq2eWxUSU6JRWK=
HT-3 M37GZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWjJR|UxRTF5LkW5NVQh|ryP MXLTRW5ITVJ?
KS-1 M2CzOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4PRb2lEPTB;MUeuOlc{KM7:TR?= MYDTRW5ITVJ?
NCI-H1792 NH2yS5NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF;XfFZKSzVyPUG3Mlc6QCEQvF2= MnzaV2FPT0WU
ABC-1 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWHJR|UxRTF5LkixOFEh|ryP NGHTTXlUSU6JRWK=
BPH-1 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MU\JR|UxRTF6LkG2PFUh|ryP MlLqV2FPT0WU
A431 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkPsTWM2OD1zOD60NVI4KM7:TR?= MWXTRW5ITVJ?
T98G NEjEb4ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX7VS|FbUUN3ME2xPE42OTV5IN88US=> MnnjV2FPT0WU
BHY MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4DycGlEPTB;MUiuPFY6KM7:TR?= NUDvXVVqW0GQR1XS
Capan-2 NYjMXmMyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml76TWM2OD1zOD65NFc5KM7:TR?= NHXxflhUSU6JRWK=
MDA-MB-175-VII M3\5emdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYG5UIV4UUN3ME2xPE46OjB7IN88US=> NV6zdYVDW0GQR1XS
CAL-27 NF\FZ3FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkT1TWM2OD1zOT6wOFg4KM7:TR?= M3zIcXNCVkeHUh?=
AsPC-1 MnfGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3HpSGlEPTB;MUmuPFY2PyEQvF2= Mn;IV2FPT0WU
KU812 NXK1OItWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV7JR|UxRTF7Lkm1O|Mh|ryP NULYVnkyW0GQR1XS
NCI-H441 MlWxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVLJR|UxRTJyLkCwNUDPxE1? M1;DUnNCVkeHUh?=
Mewo MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH35SJVKSzVyPUKwMlEzQDhizszN NFnOe4xUSU6JRWK=
SK-MEL-24 MkH5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MljFTWM2OD1{MD6xOFc4KM7:TR?= NH;1[HpUSU6JRWK=
NCI-H727 NXPIcWxtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml\YTWM2OD1{MD6yO|A1KM7:TR?= NGK2Wm9USU6JRWK=
EKVX MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVvJR|UxRTJyLk[wOkDPxE1? MV7TRW5ITVJ?
RT-112 NVHPb4NtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3;WXGlEPTB;MkCuOlEzOiEQvF2= NYGxfmRFW0GQR1XS
CAMA-1 M{n4d2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV3JdpFGUUN3ME2yNE46QDB|IN88US=> M2TLenNCVkeHUh?=
SW900 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnLBTWM2OD1{MT6wNVQ6KM7:TR?= Mm[zV2FPT0WU
NCI-H23 NEjkVWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHXBfppKSzVyPUKxMlEzPzdizszN M1zmVnNCVkeHUh?=
SK-PN-DW MoXoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MluyTWM2OD1{MT6xOlQ6KM7:TR?= M4HXZXNCVkeHUh?=
BB30-HNC NYX1bWpVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUO4Upp2UUN3ME2yNU4zPzR3IN88US=> NF3UdlZUSU6JRWK=
VM-CUB-1 NETWZplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MW\JR|UxRTJzLkO1N|Yh|ryP M3rsTHNCVkeHUh?=
IST-MEL1 M4PtTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnLjTWM2OD1{MT6zOlkzKM7:TR?= MkPkV2FPT0WU
CTB-1 Ml3NS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYDJR|UxRTJzLkS3OVUh|ryP M3nrWXNCVkeHUh?=
LCLC-103H MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEfIfYxKSzVyPUKyMlE2QDJizszN M{HjenNCVkeHUh?=
PANC-03-27 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1XaPGlEPTB;MkKuOVE3QSEQvF2= NWjPVnJGW0GQR1XS
HTC-C3 Ml3IS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVTJR|UxRTJ{LkW1OVUh|ryP Mk\iV2FPT0WU
TE-8 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NILKdVBKSzVyPUKzMlI2PjVizszN NIO5cZhUSU6JRWK=
NCI-H292 NYPIWpZnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGfGWGdKSzVyPUK1MlM2OzZizszN NUXxTnJtW0GQR1XS
COLO-680N MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3rQWGlEPTB;MkWuOlMzQSEQvF2= MkjGV2FPT0WU
KYSE-520 NUPuXmFuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFj6UGdKSzVyPUK1MlY1PCEQvF2= NVO0WnZXW0GQR1XS
NB10 M3LpfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYjJR|UxRTJ4LkOxNVch|ryP MVzTRW5ITVJ?
NCI-H661 NG\yb2RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX3JR|UxRTJ4LkS3NVMh|ryP NVHBdokyW0GQR1XS
GMS-10 MoXRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWfJR|UxRTJ4Lki2N|gh|ryP MV3TRW5ITVJ?
NCI-H2122 M1r2OGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{TQ[2lEPTB;Mk[uPVk6QCEQvF2= NXPwS2RYW0GQR1XS
OVCAR-8 NHjJUIxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnHOTWM2OD1{Nz6wOlM5KM7:TR?= MknBV2FPT0WU
DJM-1 MofTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYfFUnk{UUN3ME2yO{4yPDV2IN88US=> Mm\wV2FPT0WU
UACC-893 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MofHTWM2OD1{Nz65PFc5KM7:TR?= M4nMPXNCVkeHUh?=
C8166 M2jIXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkTqTWM2OD1{OD62PVM5KM7:TR?= NU[1OWFrW0GQR1XS
NCI-H1693 NWjDbJZ7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFPtZ|FKSzVyPUK4MlY6PzVizszN NFzhVW1USU6JRWK=
TYK-nu MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV3JR|UxRTNyLkCzOFUh|ryP NWS0fZhlW0GQR1XS
SW1710 NF;lNZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWTJR|UxRTNyLkGyOkDPxE1? M{e1bnNCVkeHUh?=
A375 Mn7KS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGXGUI5KSzVyPUOwMlMzPDNizszN MkLnV2FPT0WU
HMV-II MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmTuTWM2OD1|MT6zOVkzKM7:TR?= MkHCV2FPT0WU
NCI-H2087 MmXJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXrpS3FPUUN3ME2zNU43OzV{IN88US=> M2PBXXNCVkeHUh?=
CAL-54 M1fXeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4PRXWlEPTB;M{GuO|I1OSEQvF2= NYjhe3d3W0GQR1XS
HCC70 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXnJR|UxRTN{LkGzPFch|ryP NETifFFUSU6JRWK=
ES1 M1HUTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml;NTWM2OD1|Mj6zNFYzKM7:TR?= Mn:0V2FPT0WU
NCI-H1355 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWLNPWpWUUN3ME2zN{4zODRizszN MlLXV2FPT0WU
CFPAC-1 M{m0[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoDqTWM2OD1|Mz6yN|MzKM7:TR?= MlOxV2FPT0WU
MKN28 NWrNeGw4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXPJR|UxRTN|LkO4NFkh|ryP MYrTRW5ITVJ?
HDLM-2 NVrQV|hsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1zOWGlEPTB;M{OuOlk{OSEQvF2= MojpV2FPT0WU
PANC-10-05 NGHSR3dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NW\MPGVbUUN3ME2zOE4yODF2IN88US=> M3i5d3NCVkeHUh?=
SAS MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{i0eGlEPTB;M{SuOFU3PSEQvF2= NY\rW2VtW0GQR1XS
HCC1395 MkXzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mon5TWM2OD1|ND63NVg3KM7:TR?= MoXxV2FPT0WU
8305C M1PjPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkS2TWM2OD1|NT64OFE2KM7:TR?= MVfTRW5ITVJ?
KM12 NEXnTWVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWe3VW4{UUN3ME2zOk44PTR5IN88US=> MkTFV2FPT0WU
SW1116 M{n4d2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M37iUWlEPTB;M{euOVk6OiEQvF2= MVvTRW5ITVJ?
SK-MEL-1 NHnwVWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1rYZmlEPTB;M{iuN|M5QSEQvF2= Ml;5V2FPT0WU
HCC2218 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUfJR|UxRTN6Lk[1NVkh|ryP M{XOR3NCVkeHUh?=
T84 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVnIVZQ3UUN3ME2zPE44PDB7IN88US=> NIjsWG9USU6JRWK=
ETK-1 M4\yeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWi2[o5WUUN3ME2zPU4xOjJizszN NGXNbIJUSU6JRWK=
COLO-800 NUCxbJVJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVPHb4EyUUN3ME2zPU4{QDZ6IN88US=> MlXDV2FPT0WU
CAL-12T NG\4PG9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlvnTWM2OD1|OT61NlgyKM7:TR?= MWDTRW5ITVJ?
ACN MlHYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlP0TWM2OD12MD60PVEyKM7:TR?= NWO3VGkzW0GQR1XS
SJSA-1 NU[wVIt{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWi0R4F5UUN3ME20NU4yPTl4IN88US=> NHLxXVZUSU6JRWK=
PSN1 NFz0TlZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIGzcplKSzVyPUSxMlE4PDlizszN NFKzUoVUSU6JRWK=
D-566MG NHXTWJVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{nVbmlEPTB;NEGuNlA5PiEQvF2= MVTTRW5ITVJ?
EGI-1 NXm4PXpqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV64eFMyUUN3ME20Nk41OjhizszN M4nZPHNCVkeHUh?=
A204 NVHsb5JKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmrxTWM2OD12Mj62N|g5KM7:TR?= MX;TRW5ITVJ?
Saos-2 MmrtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXfJR|UxRTR{LkizOlkh|ryP NHjjXVVUSU6JRWK=
SNU-C2B MnLRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYrJR|UxRTR|Lk[4O|gh|ryP Ml;XV2FPT0WU
HLE NVvYeppyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mnj5TWM2OD12ND6wPFU3KM7:TR?= NGH2TYFUSU6JRWK=
SW1463 MlfNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M33WWmlEPTB;NESuPVk4OSEQvF2= M4HNfnNCVkeHUh?=
DSH1 NEPxXHRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUHJR|UxRTR3LkCwN|Mh|ryP MmjVV2FPT0WU
MCF7 MoHWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3\BSGlEPTB;NEWuOVA2OSEQvF2= MVHTRW5ITVJ?
K5 NVexeJh[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXfJR|UxRTR3Lkm0NFUh|ryP NHfm[3FUSU6JRWK=
NCI-H358 MoLuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mkm0TWM2OD12Nz6yNVUh|ryP NFfnW3JUSU6JRWK=
NCI-H2030 M4DVSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmrLTWM2OD12Nz6yN|c1KM7:TR?= MnzHV2FPT0WU
SW948 MkjrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoH2TWM2OD12Nz60OlQh|ryP NEfxRXBUSU6JRWK=
BALL-1 NVOy[4hrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2\rbWlEPTB;NEeuOlE3QCEQvF2= MnjUV2FPT0WU
TE-9 NWLaRoo4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4DSe2lEPTB;NEeuPVU5OSEQvF2= M{K1OnNCVkeHUh?=
SK-N-FI NXXrdXlsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{K5N2lEPTB;NEiuNFM2QCEQvF2= M3zqVnNCVkeHUh?=
KALS-1 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYHRfmtMUUN3ME20PE4yOjh7IN88US=> MVTTRW5ITVJ?
HO-1-N-1 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVrybFBTUUN3ME20PE44PDR3IN88US=> NGjqeG1USU6JRWK=
NCI-H2452 M1fKXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXf0fGtbUUN3ME20PU4yOTV{IN88US=> MVzTRW5ITVJ?
OC-314 M4XEUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFezc4tKSzVyPUS5MlY5OzRizszN NY\KRlNkW0GQR1XS

... Click to View More Cell Line Experimental Data

In vivo When ABT-263 is administered at 100 mg/kg/day in the H345 xenograft model, significant antitumor efficacy is observed with 80% TGI and 20% of treated tumors indicating at least a 50% reduction in tumor volume. [2] Oral administration of ABT-263 alone causes complete tumor regressions in xenograft models of small-cell lung cancer and acute lymphoblastic leukemia. In xenograft models of aggressive B-cell lymphoma and multiple myeloma where ABT-263 displays modest or no single agent activity, it significantly enhances the efficacy of clinically relevant therapeutic regimens. [2]

Protocol

Kinase Assay:

[1]

+ Expand

Affinity determination:

Binding affinities (Ki or IC50) of ABT-263 against different isoforms of Bcl-2 family are determined with competitive fluorescence polarization assays. The following peptide probe/protein pairs are used: f-bad (1 nM) and Bcl-xL (6 nM), f-Bax (1 nM) and Bcl-2 (10 nM), f-Bax (1 nM) and Bcl-w (40 nM), f-Noxa (2 nM) and Mcl-1 (40 nM), and f-Bax (1 nM) and Bcl-2-A1 (15 nM). Binding affinities for Bcl-xL are also determined using a time-resolved fluorescence resonance energy transfer assay. Bcl-xL (1 nM, His tagged) is mixed with 200 nM f-Bak, 1 nM Tb-labeled anti-His antibody, and ABT-263 at room temperature for 30 min. Fluorescence is measured on an Envision plate reader using a 340/35 nm excitation filter and 520/525 (f-Bak) and 495/510 nm (Tb-labeled anti-His antibody) emission filters.
Cell Research:

[1]

+ Expand
  • Cell lines: SCLC cell lines
  • Concentrations: 0-1 μM
  • Incubation Time: 48 hours
  • Method:

    Human tumor cell lines SCLC cell lines are maintained at 37℃ containing 5% CO2. SCLC cell lines are cultured in RPMI 1640 with 10% fetal bovine serum (FBS), 1% sodium pyruvate, 25 mM HEPES, 4.5 g/L glucose, and 1% penicillin/streptomycin. Leukemia and lymphoma cell lines are cultured in RPMI 1640 supplemented with 10% FBS and 1% penicillin/streptomycin. Cells (1-5×10 4) are treated by ABT-263 for 48 hours in 96-well culture plates in a final volume of 100 μL and cytotoxicity is assessed with the CellTiter Glo assay. In vitro cyto toxicity of ABT-263 is assayed.


    (Only for Reference)
Animal Research:

[1]

+ Expand
  • Animal Models: C.B.-17 scid-bg or C.B.-17 scid mice
  • Formulation: Formulated in 10% ethanol, 30% polyethylene glycol 400, and 60% Phosal 50 PG
  • Dosages: 100 mg/kg/d
  • Administration: Administered via p.o.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 100 mg/mL (102.6 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order:
5% DMSO+corn oil
For best results, use promptly after mixing.
7mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 974.61
Formula

C47H55ClF3N5O6S3

CAS No. 923564-51-6
Storage powder
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT02520778 Recruiting EGFR Activating Mutation|Recurrent Non-Small Cell Lung Carcinoma|Stage III Non-Small Cell Lung Cancer|Stage IIIA Non-Small Cell Lung Cancer|Stage IIIB Non-Small Cell Lung Cancer|Stage IV Non-Small Cell Lung Cancer National Cancer Institute (NCI) March 2016 Phase 1
NCT02591095 Active, not recruiting Platinum-resistant or Refractory Ovarian Cancer Centre Francois Baclesse|ARCAGY/ GINECO GROUP|French Cancer Research Hospital Program January 2016 Phase 2
NCT02143401 Recruiting Recurrent Hepatocellular Carcinoma|Solid Neoplasm|Stage IV Hepatocellular Carcinoma National Cancer Institute (NCI) November 2014 Phase 1
NCT02079740 Recruiting Advanced Solid Neoplasm|KRAS Gene Mutation|Metastatic Solid Neoplasm|NRAS Gene Mutation|Recurrent Colorectal Carcinoma|Recurrent Lung Carcinoma|Recurrent Pancreatic Carcinoma|Stage III Colorectal Cancer|Stage III Lung Cancer|Stage III Pancreatic Cancer|Stage IIIA Colorectal Cancer|Stage IIIB Colorectal Cancer|Stage IIIC Colorectal Cancer|Stage IV Colorectal Cancer|Stage IV Lung Cancer|Stage IV Pancreatic Cancer|Stage IVA Colorectal Cancer|Stage IVB Colorectal Cancer National Cancer Institute (NCI) March 2014 Phase 1|Phase 2
NCT01989585 Recruiting Metastatic Melanoma|Recurrent Melanoma|Solid Neoplasm|Stage IIIA Skin Melanoma|Stage IIIB Skin Melanoma|Stage IIIC Skin Melanoma|Stage IV Skin Melanoma National Cancer Institute (NCI) October 2013 Phase 1|Phase 2
NCT01828476 Completed Prostate Cancer Rutgers, The State University of New Jersey|Rutgers Cancer Institute of New Jersey|National Cancer Institute (NCI)|AbbVie June 2013 Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    I would like to deliver S1001 via i.p. injection, can you suggest a vehicle solution?

  • Answer:

    S1001 ABT-263 (Navitoclax) can be dissolved in 5% DMSO+corn oil at 7mg/ml as a clear solution.

  • Question 2:

    Could you tell me if the catalog number S1001 can go through the hemato-encephalic barrier?

  • Answer:

    According to the paper: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3223694/, ABT-263 can not cross brain-blood barrier.

Bcl-2 Signaling Pathway Map

Bcl-2 Inhibitors with Unique Features

Related Bcl-2 Products

Tags: buy Navitoclax (ABT-263) | Navitoclax (ABT-263) supplier | purchase Navitoclax (ABT-263) | Navitoclax (ABT-263) cost | Navitoclax (ABT-263) manufacturer | order Navitoclax (ABT-263) | Navitoclax (ABT-263) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID